Ambicare CE marks skin cancer photodynamic therapy
This article was originally published in Clinica
Executive Summary
Ambicare has CE marked its lead product, Ambulight PDT, a photodynamic therapy, for sale in Europe to treat non-melanoma skin cancer. The firm claims it is the world’s first light-emitting sticking plaster for the treatment of skin cancer.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.